{{Drugbox
| verifiedrevid = 414250678
| IUPAC_name = 8-[4,4-Bis(4-fluorophenyl)butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
| image = Fluspirilene.svg
| width = 270

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|fluspirilene}}
| pregnancy_category =  
| legal_status = Rx-only
| routes_of_administration = IM

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 1841-19-6
| ATC_prefix = N05
| ATC_suffix = AG01
| PubChem = 3396
| IUPHAR_ligand = 85
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB04842
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3279
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = C5QA4GLR9M
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D02629
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 46516

<!--Chemical data-->
| C=29 | H=31 | F=2 | N=3 | O=1
| molecular_weight = 475.573 g/mol
| smiles = Fc1ccc(cc1)C(c2ccc(F)cc2)CCCN5CCC4(C(=O)NCN4c3ccccc3)CC5
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C29H31F2N3O/c30-24-12-8-22(9-13-24)27(23-10-14-25(31)15-11-23)7-4-18-33-19-16-29(17-20-33)28(35)32-21-34(29)26-5-2-1-3-6-26/h1-3,5-6,8-15,27H,4,7,16-21H2,(H,32,35)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = QOYHHIBFXOOADH-UHFFFAOYSA-N
}}

'''Fluspirilene''' ('''Redeptin''', '''Imap''', R6218) is a [[diphenylbutylpiperidine]] [[typical antipsychotic]] [[drug]], used for the treatment of [[schizophrenia]].<ref>{{cite journal | author = van Epen JH | title =  Experience with fluspirilene (R 6218), a long-acting neuroleptic | journal = Psychiatr Neurol Neurochir | year = 1970 | volume = 73| issue = 4 | pages = 277–284 | pmid = 5478771}}</ref> It is administered [[Intramuscular injection|intramuscularly]].<ref>{{cite journal | vauthors=Janssen PA, Niemegeers CJ, Schellekens KH, Lenaerts FM, Verbruggen FJ, van Nueten JM, Marsboom RH, Hérin VV, Schaper WK | title = The pharmacology of fluspirilene (R 6218), a potent, long-acting and injectable neuroleptic drug | journal = Arzneimittelforschung | year = 1970 | volume = 20 | issue = 11 | pages = 1689–1698 | pmid = 4992598}}</ref> It was discovered at [[Janssen Pharmaceutica]] in 1963.<ref name=Janssen>C. Janssen, NV Res. Lab., {{Cite patent|BE|633914}} (1963)</ref> A 2007 [[systematic review]] investigated the efficacy of fluspirilene decanoate for people with schizophrenia:
{| class="wikitable"
|+ Fluspirilene decanoate compared to oral antipsychotics<ref name=Abh2007>{{cite journal|last1=Abhijnhan| first1=A| last2=Adams|first2=C| first3=A| last3=David|title=Depot fluspirilene for schizophrenia|journal=Cochrane Database of Systematic Reviews|date=2007|volume=1|url=http://www.cochrane.org/CD001718/SCHIZ_depot-fluspirilene-for-schizophrenia|pages=CD001718.pub2 |DOI=10.1002/14651858.CD001718.pub2}}</ref>
|-
! Summary
|-
|Participant numbers in each comparison were small so power to identify clear difference is limited. Randomized controlled trial data identified no clear differences between the long-acting injection of fluspirilene and oral medication for outcomes that include adverse effects.<ref name=Abh2007/>
|-
| style="padding:0;" |
{| class="wikitable collapsible collapsed" style="width:100%;"
|-
! scope="col" style="text-align: left;"| Outcome
! scope="col" style="text-align: left;"| Findings in words
! scope="col" style="text-align: left;"| Findings in numbers
! scope="col" style="text-align: left;"| Quality of evidence
|-
! colspan="4" style="text-align: left;"| Global outcome
|-
| Leaving the study early<br>Follow up: 6 weeks to 5 months || Fluspirilene decanoate may increase the risk of leaving the study (reasons not specified), but, the difference is not clear between people given fluspirilene decanoate and those receiving oral antipsychotics. These findings are based on data of low quality.
 || [[Relative risk|RR]] 1.18 (0.08 to 16.78) || [[The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach|Low]]
|-
! colspan="4" style="text-align: left;"| [[Mental health|Mental state]]
|-
| Relapse<br>Follow up: 6 weeks to 5 months || Using the depot, long-acting fluspirilene decanoate makes little difference for the outcome of 'relapse' compared with those receiving oral antipsychotics - at least for those willing to be engaged with trials. These findings are based on data of low quality.
 || RR 1.18 (0.08 to 16.78) || [[The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach|Low]]
|-
! colspan="4" style="text-align: left;"| [[Adverse event|Adverse effects]]
|-
| Needing anticholinergic drugs<br>Follow up: 6 weeks to 5 months || The depot fluspirilene decanoate does not seem to cause any more movement disorders - for which anticholinergic drugs are used - compared with oral antipsychotics. These findings are based on data of low quality.
 || RR 0.07 (0.00 to 1.07) || [[The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach|Low]]
|-
| Dizziness || Fluspirilene decanoate may reduce the chance of experiencing dizziness compared with the oral antipsycotics. Data are based on low quality evidence.
 || RR 0.59 (0.37 to 0.95) || [[The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach|Low]]
|-
! colspan="4" style="text-align: left;"| Missing outcomes
|-
| || Data on quality of life, and service use (e.g. hospitalization) were not reported in trials.||  || 
|-
|}
|}

==See also==
* [[Pimozide]]

==References==
{{Reflist|2}}

{{Antipsychotics}}
{{Cholinergics}}
{{Dopaminergics}}
{{Histaminergics}}
{{Serotonergics}}

[[Category:Belgian inventions]]
[[Category:Diphenylbutylpiperidines]]
[[Category:Janssen Pharmaceutica]]
[[Category:Fluoroarenes]]
[[Category:Typical antipsychotics]]
[[Category:Spiro compounds]]

{{nervous-system-drug-stub}}